MX420767B - Proteina de union al factor h modificada - Google Patents

Proteina de union al factor h modificada

Info

Publication number
MX420767B
MX420767B MX2019002248A MX2019002248A MX420767B MX 420767 B MX420767 B MX 420767B MX 2019002248 A MX2019002248 A MX 2019002248A MX 2019002248 A MX2019002248 A MX 2019002248A MX 420767 B MX420767 B MX 420767B
Authority
MX
Mexico
Prior art keywords
binding protein
modified factor
fhbp
modified
factor
Prior art date
Application number
MX2019002248A
Other languages
English (en)
Spanish (es)
Other versions
MX2019002248A (es
Inventor
Tang Christoph M
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Publication of MX2019002248A publication Critical patent/MX2019002248A/es
Publication of MX420767B publication Critical patent/MX420767B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MX2019002248A 2016-08-31 2017-08-31 Proteina de union al factor h modificada MX420767B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1614687.0A GB201614687D0 (en) 2016-08-31 2016-08-31 fHbp scaffold
PCT/GB2017/052535 WO2018042178A1 (en) 2016-08-31 2017-08-31 Modified factor h binding protein

Publications (2)

Publication Number Publication Date
MX2019002248A MX2019002248A (es) 2019-09-18
MX420767B true MX420767B (es) 2025-02-10

Family

ID=57119942

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002248A MX420767B (es) 2016-08-31 2017-08-31 Proteina de union al factor h modificada

Country Status (13)

Country Link
US (1) US12497432B2 (https=)
EP (1) EP3506934A1 (https=)
JP (1) JP7525093B2 (https=)
KR (1) KR102643280B1 (https=)
CN (1) CN109890412B (https=)
AU (1) AU2017319218B2 (https=)
BR (1) BR112019003957A2 (https=)
CA (1) CA3035159A1 (https=)
GB (2) GB201614687D0 (https=)
IL (1) IL265078B2 (https=)
MX (1) MX420767B (https=)
WO (1) WO2018042178A1 (https=)
ZA (1) ZA201901862B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
CN110903400A (zh) * 2019-11-08 2020-03-24 苏州微超生物科技有限公司 B群脑膜炎球菌fHBP多变体融合蛋白及其制备方法与应用
CN111533792B (zh) * 2020-07-07 2020-10-16 康希诺生物股份公司 一种定点突变的载体蛋白及其在制备疫苗中的用途
US20230365979A1 (en) * 2020-09-29 2023-11-16 Idemitsu Kosan Co.,Ltd. Peptide tag and tagged protein including same
IN202321021121A (https=) * 2023-03-24 2024-04-19

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
HUE031886T2 (en) * 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
EP1572234B1 (en) * 2002-12-10 2012-02-22 Sanofi Pasteur Biologics Co. STABILIZED IMMUNOGENIC HBc CHIMER PARTICLES
ES2461350T3 (es) * 2003-01-30 2014-05-19 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
CN103357002A (zh) * 2003-10-02 2013-10-23 诺华疫苗和诊断有限公司 多种脑膜炎球菌血清群的液体疫苗
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
DE602005025647D1 (de) * 2004-07-23 2011-02-10 Novartis Vaccines & Diagnostic Polypeptide für die oligomerisierung von antigenen
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
ES2616294T3 (es) * 2005-01-27 2017-06-12 Children's Hospital & Research Center At Oakland Vacunas de vesículas basadas en GNA1870 para protección de amplio espectro contra enfermedades provocadas por Neisseria meningitidis
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
CN102356089B (zh) * 2008-02-21 2014-02-19 诺华股份有限公司 脑膜炎球菌fHBP多肽
ES2557282T3 (es) * 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
JP5723768B2 (ja) * 2008-05-30 2015-05-27 ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー オブ ジ アーミー， オン ビハーフ オブ ウォルター リード アーミー インスティチュート オブ リサーチ 髄膜炎菌性多価未変性外膜小胞ワクチン、その作製方法およびその使用
US20100105875A1 (en) * 2008-06-09 2010-04-29 Maria Scarselli Antibodies against neisserial factor H binding protein
WO2010028096A2 (en) * 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
HUE049695T2 (hu) * 2009-03-24 2020-10-28 Glaxosmithkline Biologicals Sa Adjuváló H meningococcus faktort kötõ fehérje
CA2759400A1 (en) * 2009-04-30 2010-11-04 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) and methods of use
US20110076300A1 (en) * 2009-08-27 2011-03-31 Mariagrazia Pizza Hybrid Polypeptides Including Meningococcal fHBP Sequences
CA2779816A1 (en) * 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
EP2544714A1 (en) * 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Vaccine composition
ES2910199T3 (es) * 2010-03-30 2022-05-11 Childrens Hospital & Res Center At Oakland Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas
EP2556085A2 (en) * 2010-04-05 2013-02-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
CA2803239A1 (en) * 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
NZ607224A (en) * 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
WO2013078223A1 (en) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
EP2797624A1 (en) * 2011-12-29 2014-11-05 Novartis AG Adjuvanted combinations of meningococcal factor h binding proteins
JP2015517089A (ja) * 2012-03-08 2015-06-18 ノバルティス アーゲー タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ
MX359256B (es) * 2012-03-09 2018-09-19 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
SA115360586B1 (ar) * 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX357538B (es) * 2012-06-14 2018-07-13 Novartis Ag Vacunas para meningococo de serogrupo x.
GB201215005D0 (en) * 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
US9802987B2 (en) * 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
US20160030544A1 (en) * 2013-03-14 2016-02-04 Isis Innovation Limited Immunogenic composition to neisseria
RU2662968C2 (ru) * 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
JP6786394B2 (ja) * 2014-02-28 2020-11-18 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 改変髄膜炎菌ｆＨｂｐポリペプチド
CA3212723A1 (en) * 2014-07-23 2016-01-28 Peter T. Beernink Factor h binding protein variants and methods of use thereof
US20170326220A1 (en) * 2014-11-28 2017-11-16 Janssen Vaccines & Prevention B.V. Meningitis b vaccine
AU2016221318B2 (en) * 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
AU2018215585B2 (en) * 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Also Published As

Publication number Publication date
EP3506934A1 (en) 2019-07-10
AU2017319218A2 (en) 2019-05-02
CA3035159A1 (en) 2018-03-08
AU2017319218B2 (en) 2021-10-28
IL265078A (https=) 2019-04-30
IL265078B1 (en) 2023-04-01
CN109890412B (zh) 2025-04-04
KR102643280B1 (ko) 2024-03-05
US12497432B2 (en) 2025-12-16
IL265078B2 (en) 2023-08-01
CN109890412A (zh) 2019-06-14
GB201903866D0 (en) 2019-05-08
ZA201901862B (en) 2020-09-30
MX2019002248A (es) 2019-09-18
GB2568440B (en) 2022-08-17
NZ751995A (en) 2024-03-22
GB201614687D0 (en) 2016-10-12
JP7525093B2 (ja) 2024-07-30
BR112019003957A2 (pt) 2019-06-25
GB2568440A (en) 2019-05-15
AU2017319218A1 (en) 2019-04-18
KR20190064577A (ko) 2019-06-10
JP2019526261A (ja) 2019-09-19
US20220112249A1 (en) 2022-04-14
WO2018042178A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
CL2019003892A1 (es) Nuevos derivados de azaquinolina.
PH12020550051A1 (en) Glp-1 compositions and uses thereof
BR112018071678A2 (pt) compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv
UY37480A (es) Nuevos derivados de quinolina
MX2023003875A (es) Formulacion de una vacuna peptidica.
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
MX420767B (es) Proteina de union al factor h modificada
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
MX364942B (es) Peptidos antimicrobianos.
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
PH12020500569A1 (en) Influenza virus vaccines and uses thereof
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
PH12017500450A1 (en) Flavivirus virus like particle
PY2188555A (es) Composiciones y métodos para la prevención y/o tratamiento de la covid-19
EA202091308A1 (ru) Модифицированный вакцинный штамм brucella для лечения бруцеллеза
MX2020008125A (es) Composiciones que comprenden berberina.
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها
UA118542C2 (uk) Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197
WO2016100615A3 (en) Methods and composition for neutralization of influenza
MX362058B (es) Péptido pntx(19) sintético, composición farmacéutica y uso.
WO2016172269A3 (en) Insulin analogs having shortened b chain peptides and associated methods
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
PY2285025A (es) Composiciones y métodos para la prevención y/o tratamiento de la covid-19
MX381255B (es) Vacunas contra el reovirus aviar.
EA201890209A1 (ru) Композиция, содержащая танины